The stock price of Rani Therapeutics Holdings Inc (NASDAQ: RANI) has dropped by -7.39 compared to previous close of 2.57. Despite this, the company has seen a gain of 12.26% in its stock price over the last five trading days. globenewswire.com reported 2024-10-15 that SAN JOSE, Calif., Oct. 15, 2024 (GLOBE NEWSWIRE) — Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it has entered into a securities purchase agreement with a single institutional investor for the purchase and sale of 3,000,000 shares of Rani Therapeutics’ Class A common stock (the “Common Stock”) and pre-funded warrants to purchase 333,333 shares of Common Stock, together with Series C common warrants to purchase up to an aggregate of 3,333,333 shares of Common Stock, in a registered direct offering. Each share of Common Stock (or pre-funded warrant) is being sold together with one Series C common warrant at a combined purchase price of $3.00. The Series C common warrants will have an exercise price of $3.00 per share and will expire 5 years from the date of issuance.
Is It Worth Investing in Rani Therapeutics Holdings Inc (NASDAQ: RANI) Right Now?
Additionally, the 36-month beta value for RANI is 0.14. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for RANI is 18.82M and currently, short sellers hold a 4.19% ratio of that float. The average trading volume of RANI on October 23, 2024 was 1.43M shares.
RANI’s Market Performance
RANI’s stock has seen a 12.26% increase for the week, with a 9.17% rise in the past month and a -16.49% fall in the past quarter. The volatility ratio for the week is 12.03%, and the volatility levels for the past 30 days are at 14.12% for Rani Therapeutics Holdings Inc. The simple moving average for the past 20 days is 1.41% for RANI’s stock, with a -36.14% simple moving average for the past 200 days.
Analysts’ Opinion of RANI
Many brokerage firms have already submitted their reports for RANI stocks, with Oppenheimer repeating the rating for RANI by listing it as a “Outperform.” The predicted price for RANI in the upcoming period, according to Oppenheimer is $17 based on the research report published on August 02, 2024 of the current year 2024.
Maxim Group, on the other hand, stated in their research note that they expect to see RANI reach a price target of $15. The rating they have provided for RANI stocks is “Buy” according to the report published on June 14th, 2024.
Rodman & Renshaw gave a rating of “Buy” to RANI, setting the target price at $10 in the report published on June 13th of the current year.
RANI Trading at -6.79% from the 50-Day Moving Average
After a stumble in the market that brought RANI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -72.80% of loss for the given period.
Volatility was left at 14.12%, however, over the last 30 days, the volatility rate increased by 12.03%, as shares surge +8.18% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +0.34% upper at present.
During the last 5 trading sessions, RANI rose by +12.26%, which changed the moving average for the period of 200-days by -20.13% in comparison to the 20-day moving average, which settled at $2.35. In addition, Rani Therapeutics Holdings Inc saw -28.31% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RANI starting from South Cone Investments Limited, who sale 3,829,360 shares at the price of $2.65 back on Oct 15 ’24. After this action, South Cone Investments Limited now owns 8,302,194 shares of Rani Therapeutics Holdings Inc, valued at $10,141,674 using the latest closing price.
Quiroga Cortes Isidoro Alfonso, the 10% Owner of Rani Therapeutics Holdings Inc, sale 5,265,165 shares at $2.01 during a trade that took place back on Nov 24 ’23, which means that Quiroga Cortes Isidoro Alfonso is holding 8,400 shares at $10,582,982 based on the most recent closing price.
Stock Fundamentals for RANI
Current profitability levels for the company are sitting at:
- -21.04 for the present operating margin
- 0.56 for the gross margin
The net margin for Rani Therapeutics Holdings Inc stands at -11.12. The total capital return value is set at -2.13. Equity return is now at value -227.14, with -48.07 for asset returns.
Based on Rani Therapeutics Holdings Inc (RANI), the company’s capital structure generated 0.92 points at debt to capital in total, while cash flow to debt ratio is standing at -1.47. The debt to equity ratio resting at 10.89. The interest coverage ratio of the stock is -11.16.
Currently, EBITDA for the company is -65.28 million with net debt to EBITDA at -0.54. When we switch over and look at the enterprise to sales, we see a ratio of 57.21. The receivables turnover for the company is 27.5for trailing twelve months and the total asset turnover is 0.06. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.93.
Conclusion
In conclusion, Rani Therapeutics Holdings Inc (RANI) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
